On 4th September, EpimAb Biotherapeutics, Inc. ("EpimAb" or "EpimAb Biotherapeutics") a clinical stage biopharmaceutical company specializing in the discovery and development of multi-specific antibodies for diseases with high unmet need, and Vignette Bio, Inc. ("Vignette" or "Vignette Bio") a clinical stage company incubated by Foresite Labs and backed by Foresite Capital, Qiming Venture Partners USA, Samsara BioCapital, and Mirae Asset Capital Life Science, announced today that EpimAb and Vignette have entered into a license agreement for EpimAb's BCMA-targeting T-cell engager (TCE) EMB-06.
Under this agreement, EpimAb will grant Vignette the exclusive rights to develop and commercialize EMB-06 outside of Greater China (mainland China, Hong Kong, Macau and Taiwan), while EpimAb shall retain the rights to EMB-06 in Greater China. EpimAb will receive total upfront considerations of $60 million in cash and equity of Vignette, and will be eligible to receive up to $575 million development, regulatory and commercial milestones, plus royalties on net sales.
Sep 25, 2024
